Causal effects of lipid-lowering therapies on aging-related outcomes and risk of cancers: a drug-target Mendelian randomization study
Aging · 2023
DOI: 10.18632/aging.205347 ↗At a glance
Journal article in Aging, 2023. Written by Han Chen and 7 co-authors. Institution: Department of Gastroenterology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China. Major MEDLINE topics: Diabetes Mellitus, Type 2, Neoplasms. Cited 6 times so far (Crossref); 34 references. The full text is freely available in PubMed Central.
Abstract (original language)
BACKGROUND: Despite the widespread use of statins, newer lipid-lowering drugs have been emerging. It remains unclear how the long-term use of novel lipid-lowering drugs affects the occurrence of cancers and age-related diseases. METHODS: A drug-target Mendelian randomization study was performed. Genetic variants of nine lipid-lowering drug-target genes (HMGCR, PCKS9, NPC1L1, LDLR, APOB, CETP, LPL, APOC3, and ANGPTL3) were extracted as exposures from the summary data of Global Lipids Genetics Consortium Genome-Wide Association Studies (GWAS). GWAS summary data of cancers and noncancerous diseases were used as outcomes. The inverse-variance weighted method was applied as the main statistical approach. Sensitivity tests were conducted to evaluate the robustness, pleiotropy, and heterogeneity of the results. RESULTS: In addition to marked effects on decreased risks of atherosclerotic cardiovascular diseases, genetically proxied lipid-lowering variants of PCKS9, CETP, LPL, LDLR, and APOC3 were associated with longer human lifespans (q
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Gastroenterology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
- Department of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
- Department of Neurology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
Cite
APA
Chen, H., Tang, X., Su, W., Li, S., Yang, R., Cheng, H., Zhang, G., & Zhou, X. (2023). Causal effects of lipid-lowering therapies on aging-related outcomes and risk of cancers: a drug-target Mendelian randomization study. Aging. https://doi.org/10.18632/aging.205347
Vancouver
Chen H, Tang X, Su W, Li S, Yang R, Cheng H, et al. Causal effects of lipid-lowering therapies on aging-related outcomes and risk of cancers: a drug-target Mendelian randomization study. Aging. 2023. doi:10.18632/aging.205347
BibTeX
@article{Chen2023,
author = {Chen, Han and Tang, Xinyu and Su, Wei and Li, Shuo and Yang, Ruoyun and Cheng, Hong and Zhang, Guoxin and Zhou, Xiaoying},
title = {Causal effects of lipid-lowering therapies on aging-related outcomes and risk of cancers: a drug-target Mendelian randomization study},
journal = {Aging},
year = {2023},
doi = {10.18632/aging.205347}
}
EUVIMED